Drew M. Pardoll

Drew M. Pardoll

Auto-generated profile, based on publicly available information

Drew M. Pardoll

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
HYHua Yu
Hua Yu
DPDrew Pardoll
Drew Pardoll
RJRichard Jove
Richard Jove

1 September 2011 in Cell
Verified
Journal Article
Closed access
EDEric V. Dang
Eric V. Dang
JBJoseph Barbi
Joseph Barbi
HYHuang-Yu Yang
Huang-Yu Yang
DJDilini Jinasena
Dilini Jinasena
HYHong Yu
Hong Yu
FPFan Pan
Fan Pan

31 January 2020 in Science
Verified
Journal Article
Closed access
PDF file
STSuzanne L. Topalian
Suzanne L. Topalian
JTJanis M. Taube
Janis M. Taube
DPDrew M. Pardoll
Drew M. Pardoll
Presurgical immune checkpoint blockade: Checkpoint blockade immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al. review advances in neoadjuvant (presurgical) immunotherapy as an important next step for enhancing the response of early-stage tumors to immune checkpoint blockade. They highlight the mechanistic rationale for neoadjuvant immunotherapy and recent neoadjuvant clinical trials based on anti–PD-1 or anti–PD-1 ligand 1 (anti–PD-L1) therapy. Pathological assessment criteria that may provide early on-treatment biomarkers to predict patient response are also discussed. Science , this issue p. eaax0182

29 June 2009 in Journal of Experimental Medicine
Verified
Journal Article
Open access
LWLin Wang
Lin Wang
TYTangsheng Yi
Tangsheng Yi
MKMarcin Kortylewski
Marcin Kortylewski
DPDrew M. Pardoll
Drew M. Pardoll
DZDefu Zeng
Defu Zeng
HYHua Yu
Hua Yu
Although the Th17 subset and its signature cytokine, interleukin (IL)-17A (IL-17), are implicated in certain autoimmune diseases, their role in cancer remains to be further explored. IL-17 has been shown to be elevated in several types of cancer, but how it might contribute to tumor growth is still unclear. We show that growth of B16 melanoma and MB49 bladder carcinoma is reduced in IL-17−/− mice but drastically accelerated in IFN-γ−/− mice, contributed to by elevated intratumoral IL-17, indicating a role of IL-17 in promoting tumor growth. Adoptive transfer studies and analysis of the tumor microenvironment suggest that CD4+ T cells are the predominant source of IL-17. Enhancement of tumor growth by IL-17 involves direct effects on tumor cells and tumor-associated stromal cells, which bear IL-17 receptors. IL-17 induces IL-6 production, which in turn activates oncogenic signal transducer and activator of transcription (Stat) 3, up-regulating prosurvival and proangiogenic genes. The Th17 response can thus promote tumor growth, in part via an IL-6–Stat3 pathway.

2 April 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
STSu-Yi Tseng
Su-Yi Tseng
MOMizuto Otsuji
Mizuto Otsuji
KGKevin Gorski
Kevin Gorski
XHXin Huang
Xin Huang
JSJill E. Slansky
Jill E. Slansky
HTHaruo Tsuchiya
Haruo Tsuchiya
Dendritic cells (DCs), unique antigen-presenting cells (APCs) with potent T cell stimulatory capacity, direct the activation and differentiation of T cells by providing costimulatory signals. As such, they are critical regulators of both natural and vaccine-induced immune responses. A new B7 family member, B7-DC, whose expression is highly restricted to DCs, was identified among a library of genes differentially expressed between DCs and activated macrophages. B7-DC fails to bind the B7.1/2 receptors CD28 and cytotoxic T lymphocyte–associated antigen (CTLA)-4, but does bind PD-1, a receptor for B7-H1/PD-L1. B7-DC costimulates T cell proliferation more efficiently than B7.1 and induces a distinct pattern of lymphokine secretion. In particular, B7-DC strongly costimulates interferon γ but not interleukin (IL)-4 or IL-10 production from isolated naive T cells. These properties of B7-DC may account for some of the unique activity of DCs, such as their ability to initiate potent T helper cell type 1 responses.

1 April 2009 in Cancer Cell
Verified
Journal Article
Closed access
HLHeehyoung Lee
Heehyoung Lee
AHAndreas Herrmann
Andreas Herrmann
JDJie-Hui Deng
Jie-Hui Deng
MKMaciej Kujawski
Maciej Kujawski
GNGuilian Niu
Guilian Niu
HYHua Yu
Hua Yu